CRA Insights

When a copy is not a copy: biosimilars v. generics

February 11, 2014

Accounting for the differences and understanding the appropriate way to model the marketplace for biosimilars, as opposed to generics, may have significant consequences for economic analyses in the context of litigation. In this article, we identify some of those differences and their implications.

Related Capabilities

Meet the authors